Browse
Submit Data
Databases
API
Help

Dataset Information

27 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

ABSTRACT:

SUBMITTER: Schmidt AF

PROVIDER: S-EPMC6478267 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC8094613 | biostudies-literature

PCSK9 inhibitors in the prevention of cardiovascular disease.

Project description:Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with currently available lipid-lowering drugs. Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic strategy to reduce residual cardiovascular disease risk. Binding of PCSK9 to the LDL receptor targets the receptor for lysosomal degradation. The recognition that inhibition of PCSK9 increases LDL receptor activity has led to the development of a number of approaches to directly target PCSK9. Numerous monoclonal antibodies against PCSK9 are currently being evaluated in phase 3 trials, involving various patient categories on different background lipid-lowering therapies. Current evidence shows reductions in LDL-C levels of up to 70 % may be achieved with PCSK9 inhibition, independent of background statin therapy. This review examines the most recent evidence and future prospects for the use of PCSK9 inhibitors in the prevention of cardiovascular disease.

| S-EPMC5010583 | biostudies-literature

Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC6414510 | biostudies-literature

Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC6517012 | biostudies-literature

Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC6513571 | biostudies-literature

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).

Project description:General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).

| S-EPMC5352782 | biostudies-literature

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC7049091 | biostudies-literature

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC6513557 | biostudies-literature

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Project description: Not available

| S-EPMC6517311 | biostudies-literature

Niacin for primary and secondary prevention of cardiovascular events.

Project description: Not available